Related Experiment Video
Updated: Jul 23, 2026

The Soft Agar Colony Formation Assay
Published on: October 27, 2014
Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1
I A Drummond1, S L Madden, P Rohwer-Nutter
1Howard Hughes Medical Institute, University of Chicago, IL 60637.
Abstract:
The Wilms tumor suppressor gene wt1 encodes a zinc finger DNA binding protein, WT1, that functions as a transcriptional repressor. The fetal mitogen insulin-like growth factor II (IGF-II) is overexpressed in Wilms tumors and may have autocrine effects in tumor progression. The major fetal IGF-II promoter was defined in transient transfection assays as a region spanning from nucleotides -295 to +135, relative to the transcription start site. WT1 bound to multiple sites in this region and functioned as a potent repressor of IGF-II transcription in vivo. Maximal repression was dependent on the presence of WT1 binding sites on each side of the transcriptional initiation site. These findings provide a molecular basis for overexpression of IGF-II in Wilms tumors and suggest that WT1 negatively regulates blastemal cell proliferation by limiting the production of a fetal growth factor in the developing vertebrate kidney.
Insights
The Wilms tumor suppressor gene WT1 acts as a repressor, controlling insulin-like growth factor II (IGF-II) transcription. This finding explains IGF-II overexpression in Wilms tumors and WT1's role in kidney development.
Area of Science:
- Molecular Biology
- Developmental Biology
- Cancer Genetics
Background:
- Wilms tumor is a pediatric kidney cancer often associated with overexpression of insulin-like growth factor II (IGF-II), a fetal mitogen.
- The Wilms tumor suppressor gene (WT1) encodes a transcription factor that typically acts as a repressor.
Purpose of the Study:
- To investigate the molecular mechanism by which WT1 regulates IGF-II transcription.
- To determine if WT1 directly represses the IGF-II promoter and its role in Wilms tumor pathogenesis.
Main Methods:
- Transient transfection assays were used to define the major fetal IGF-II promoter region.
- WT1 binding to the IGF-II promoter was assessed in vivo.
- Reporter gene assays were employed to measure WT1's repressive activity on IGF-II transcription.
Main Results:
- The major fetal IGF-II promoter was mapped to a region from nucleotides -295 to +135.
- WT1 was found to bind to multiple sites within this promoter region.
- WT1 demonstrated potent repression of IGF-II transcription in vivo, with maximal repression dependent on WT1 binding sites flanking the transcription start site.
Conclusions:
- WT1 directly represses the major fetal IGF-II promoter, providing a molecular explanation for IGF-II overexpression in Wilms tumors.
- WT1 negatively regulates blastemal cell proliferation by limiting IGF-II production during kidney development.
- These findings highlight a critical regulatory axis in kidney development and Wilms tumorigenesis.
Related Concept Videos
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Canonical Wnt Signaling Pathway
Abnormal Proliferation
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

